Regorafenib is an oral multi-kinase inhibitor tablet, commonly known by the brand name Stivarga, approved for the treatment of metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma. The medication operates by inhibiting specific kinases, which helps slow tumor growth and restricts the blood supply to cancer cells.